||2 years -20¡ãC Powder, 2 weeks4¡ãC in DMSO,6 months-80¡ãC in DMSO
Note: Products for research use only, not for human use
NVP-AEW541 is a pyrrolo[2,3-d]pyrimidine derivative small molecular weight kinase inhibitor of the IGF-IR, capable of distinguishing between the IGF-IR (IC50 = 0.086 microM) and the closely related InsR (IC50 = 2.3 microM) in cells. As expected For a specific IGF-IR kinase inhibitor, NVP-AEW541 abrogates IGF-I-mediated survival and colony Formation in soft agar at concentrations that are consistent with inhibition of IGF-IR autophosphorylation. In vivo, this orally bioavailable compound inhibits IGF-IR signaling in tumor xenografts and significantly reduces the growth of IGF-IR-driven fibrosarcomas. Thus, NVP-AEW541 represents a class of selective, small molecule IGF-IR kinase inhibitors with proven in vivo antitumor activity and potential therapeutic application. (Source: Garc¨ªa-Echeverr¨ªa C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, Gao J, Brueggen J, Capraro HG, Cozens R, Evans DB, Fabbro D, Furet P, Porta DG, Liebetanz J, Martiny-Baron G, Ruetz S, Hofmann F. Cancer Cell. 2004 Mar;5(3):231-9.)
For the detailed information about the solubility of NVP-AEW541 in water, the solubility of NVP-AEW541 in DMSO, the solubility of NVP-AEW541 in PBS buffer, the animal experiment£¨test£© of NVP-AEW541, the in vivo,in vitro and clinical trial test of NVP-AEW541, the cell experiment£¨test£© of NVP-AEW541, the IC50, EC50 and Affinity of NVP-AEW541 , please contact DC Chemicals.